Inhibitors of the ALK and EGF receptor tyrosine kinases provoke dramatic but short-lived responses in lung cancers harboring EML4-ALK translocations or activating mutations of EGFR, respectively. We used a large-scale RNAi screen to identify MED12, a component of the transcriptional MEDIATOR complex that is mutated in cancers, as a determinant of response to ALK and EGFR inhibitors. MED12 is in part cytoplasmic where it negatively regulates TGFbR2 through physical interaction. MED12 suppression therefore results in activation of TGF-bR signaling, which is both necessary and sufficient for drug resistance. TGF-b signaling causes MEK/ERK activation, and consequently MED12 suppression also confers resistance to MEK and BRAF inhibitors in other cancers. MED12 loss induces an EMT-like phenotype, which is associated with chemotherapy resistance in colon cancer patients and to gefitinib in lung cancer. Inhibition of TGF-bR signaling restores drug responsiveness in MED12 KD cells, suggesting a strategy to treat drug-resistant tumors that have lost MED12.
SUMMARY
Inhibitors of the ALK and EGF receptor tyrosine kinases provoke dramatic but short-lived responses in lung cancers harboring EML4-ALK translocations or activating mutations of EGFR, respectively. We used a large-scale RNAi screen to identify MED12, a component of the transcriptional MEDIATOR complex that is mutated in cancers, as a determinant of response to ALK and EGFR inhibitors. MED12 is in part cytoplasmic where it negatively regulates TGFbR2 through physical interaction. MED12 suppression therefore results in activation of TGF-bR signaling, which is both necessary and sufficient for drug resistance. TGF-b signaling causes MEK/ERK activation, and consequently MED12 suppression also confers resistance to MEK and BRAF inhibitors in other cancers. MED12 loss induces an EMT-like phenotype, which is associated with chemotherapy resistance in colon cancer patients and to gefitinib in lung cancer. Inhibition of TGF-bR signaling restores drug responsiveness in MED12 KD cells, suggesting a strategy to treat drug-resistant tumors that have lost MED12.
INTRODUCTION
Cancer therapy is often hampered by the rapid emergence of drug resistance. This is true not only for the conventional chemotherapies but also for the new generation of drugs targeting those components that are mutated or deregulated in tumor cells. For example, treatment of metastatic non-small-cell lung cancers (NSCLCs) harboring activating mutations in the gene encoding the epidermal growth factor receptor (EGFR) leads to significant increases in progression-free survival. However, such responses are often short-lived, resulting in much less impressive patient benefit in terms of overall survival (Maemondo et al., 2010) . This lack of long-term benefit is due to the emergence of drug-resistant variants. Development of resistance to targeted therapies is a general phenomenon and is also seen in BCR-ABL-translocated chronic myelogenous leukemias (CML) treated with imatinib (Gorre et al., 2001) , BRAF mutant melanomas treated with the BRAF inhibitor vemurafenib (Chapman et al., 2011) , and EML4-ALK-translocated NSCLCs treated with the ALK inhibitor crizotinib (Kwak et al., 2010) .
About half of the resistance seen in EGFR mutant NSCLCs treated with EGFR inhibitors can be explained by secondary mutations in the EGFR gene itself (Sequist et al., 2011) . The T790M ''gatekeeper'' mutation in EGFR is critical for binding of competitive inhibitors to the ATP-binding pocket (Yun et al., 2008) , allowing continued proliferation in the presence of the drug. Similar gatekeeper mutations have been found in BCR-ABL-positive CMLs treated with imatinib (Shah et al., 2002) and in EML4-ALK mutant NSCLCs treated with crizotinib (Choi et al., 2010) .
Resistance to targeted therapies that does not involve secondary mutations in the drug target itself is often caused by mutations in the signaling pathway downstream of the target. Thus, primary resistance to EGFR-targeted therapy in colon cancer is associated with mutations in KRAS (Karapetis et al., (A) Schematic outline of the crizotinib resistance barcode screen performed in H3122 cells. NKI human shRNA library polyclonal virus was used to infect H3122 cells, which were then left untreated (control) or treated with 300 nM crizotinib for 14 or 28 days, respectively. After selection, shRNA inserts from both populations were recovered, labeled, and hybridized to DNA oligonucleotide barcode arrays. (B) Analysis of the relative abundance of the recovered shRNA cassettes from crizotinib barcode experiment. Averaged data from three independent experiments were normalized and 2log transformed. Among the 43 top shRNA candidates (M > 2 and A > 7), two independent shMED12 vectors (in red) were identified. (C-E) Three independent shRNAs targeting MED12 confer resistance to ALK inhibitors. (C) The functional phenotypes of nonoverlapping retroviral shMED12 vectors (#1-3) in H3122 cells are indicated by colony formation assay in 300 nM crizotinib or 2.5 nM NVP-TAE684. The pRS vector was used as a control. The cells 2008) . Similarly, acquired resistance to BRAF inhibition in melanoma can result from an activating mutation in the MEK1 kinase that was not detectable in the primary tumor (Wagle et al., 2011) . Alternatively, resistance can result from activation of a parallel pathway or in genes that feed into the downstream signaling of the drug target. Thus, amplification of the MET oncogene is found in EGFR drug-resistant NSCLC (Sequist et al., 2011) , and overexpression of COT, leading to activation of MEK, can be a causal agent in BRAF resistance in melanoma (Johannessen et al., 2010) . At present, some 30% of the resistance to EGFR-targeted therapies in NSCLCs cannot be explained by any of the mechanisms described above (Sequist et al., 2011) .
Functional genetic screens provide a powerful tool to identify novel components of signaling pathways and can help to identify mechanisms of drug resistance in preclinical models of cancer (Berns et al., 2007; Hö lzel et al., 2010) . We describe here the use of a large-scale loss-of-function genetic screen to identify genes whose suppression can confer resistance to crizotinib in a NSCLC cell line harboring an EML4-ALK translocation. We identify a key component of the transcriptional MEDIATOR complex, MED12, as a determinant of crizotinib response in NSCLC. Remarkably, we find that suppression of MED12 also confers resistance to a range of cancer drugs, including chemotherapy, in colon cancer, melanoma, and liver cancer. We identify an unexpected activity of MED12 in regulating transforming growth factor b (TGF-b) receptor signaling, as the major mechanism of drug-resistance induction.
RESULTS

MED12 Suppression Confers Resistance to Multiple Tyrosine Kinase Inhibitors in NSCLCs
The NSCLC cell line H3122 harbors an EML4-ALK translocation and is exquisitely sensitive to the ALK inhibitors PF-02341066 (crizotinib) and NVP-TAE684 (McDermott et al., 2008) . To identify genetic determinants of resistance to ALK inhibitors in EML4-ALK-translocated NSCLC, we performed a large-scale RNA interference (RNAi) genetic screen with a collection of 24,000 short hairpin RNA (shRNA) vectors targeting 8,000 human genes (Berns et al., 2004) . As outlined in Figure 1A , we used a barcoding technology to identify genes whose suppression causes resistance to crizotinib in H3122 cells (Brummelkamp et al., 2006; Hö lzel et al., 2010) . The results are shown in Figure 1B . Each dot in the M/A-plot represents one individual shRNA vector. M and A values reflect relative enrichment and hybridization signal intensity. Low-intensity spots are prone to technical artifacts and are thus unreliable. Therefore we restricted our candidate selection by applying M/A cut-off values as indicated in Figure 1B . To rule out ''off-target'' effects, we prioritized genes that are present with multiple shRNAs. Only one gene fulfilled these criteria: MED12 encoding a component of the large MEDIATOR transcriptional adaptor complex.
To validate MED12 as a gene whose suppression confers resistance to crizotinib, we introduced the two MED12 shRNAs (#1 and #2) from the library and one newly generated shRNA (#3) into H3122 cells by retroviral infection. Empty vector (pRS) or shRNA-targeting GFP (shGFP) served as controls. All three distinct MED12 shRNAs conferred resistance to both crizotinib and NVP-TAE684 ( Figure 1C ) and also suppressed MED12 mRNA and protein expression ( Figures 1D and 1E) . Expression of additional independent lentiviral shMED12 vectors (#4 and #5) in H3122 cells also conferred resistance to ALK inhibitors (Figures S1A-S1C available online and data not shown). Furthermore, reconstitution of the RNAi-resistant murine Med12 cDNA in MED12 knockdown (MED12 KD ) H3122 cells restored the sensitivity of these cells to ALK inhibition ( Figure S1 ). Figure 2F and data not shown) and conferred resistance to AZD6244 ( Figure 2E Figure 3A ; see Experimental Procedures) is the inverse of the resistance screen shown in Figures 1A and 1B as here we select for shRNAs that are depleted upon drug treatment rather than enriched. Among the top 51 candidates that met the selection criterion described in Figure 3B , only one gene, transforming growth factor b receptor II (TGF-bR2), was represented by two independent shRNAs. This suggests that suppression of TGF-bR2 synergizes with ALK inhibition in MED12 KD cells. To validate this, we infected the same MED12 KD H3122 cells with each of these two shTGF-bR2 vectors (both reduced TGF-bR2 levels; Figure 3D ) and cultured these cells with or without crizotinib for 2 weeks. Suppression of TGF-bR2 in combination with crizotinib caused a marked inhibition of proliferation in MED12 KD cells ( Figure 3C ). These findings indicate that suppression of TGF-bR2 resensitizes the MED12 KD cells to ALK inhibition and suggest that TGF-b signaling is required for the drug resistance caused by MED12 loss.
TGF-b Signaling Is Sufficient to Confer Resistance to a Variety of Cancer Drugs
Overexpression of exogenous TGF-bR2 was sufficient to activate TGF-b signaling and confer resistance to crizotinib in H3122 cells ( Figure 3E ). Consistently, recombinant TGF-b treatment also caused resistance to crizotinib in H3122 cells ( Figure 3G ). Furthermore, TGF-b treatment also caused MEK/ERK activation, consistent with the established activity of TGF-b in non-SMAD pathway signaling (Zhang, 2009 ) ( Figure S4B ). These data indicate that TGF-b activation is sufficient to confer resistant to ALK inhibitors in EML4-ALKpositive NSCLCs.
TGF-b treatment also caused MEK/ERK activation and conferred resistance to EGFR inhibitors in PC9 and H3255 NSCLC cells (Figures S3E and S4A and data not shown). Similarly, TGF-b-induced resistance to AZD6244 and PLX4032 was also observed in CRC cells and melanoma cells (Figures S3F, S3G, and S4C) . Finally, TGF-b treatment also conferred resistance to cisplatin (Figures S3H and S3I) . In some cells such as A375 and Huh-7 ( Figure S3G and data not shown), recombinant TGF-b treatment alone resulted in growth inhibition but clearly became beneficial when cells were cultured in the presence of targeted cancer drugs, mimicking the effects of MED12 KD in the same cells ( Figures 2C and 2G ). These results demonstrate that activation of TGF-b signaling is sufficient to confer resistance to multiple cancer drugs in the cancer types in which MED12 KD also confers drug resistance.
Downregulation of MED12 Activates TGF-b Signaling by Elevating TGF-bR2 Protein Levels
Our findings suggested that MED12 acts as a suppressor of TGF-b signaling. We explored this by studying gene-expression analysis using transcriptome sequencing (RNA-Seq) in a panel of cells lines (H3122, PC9, SK-CO-1, A375, and Huh-7) and multiple MED12 KD derivatives thereof. The genes deregulated by MED12 KD (>2-fold) in at least three out of five cell lines used are listed in Table S2A We also observed induction of these TGF-b target genes upon MED12 KD in other tumor types including melanoma, colon cancer, and hepatocellular carcinoma (HCC) (Figures S5A-S5D). It is well-established that TGF-b induces an epithelialmesenchymal transition (EMT), leading to the induction of several mesenchymal markers such as Vimentin (VIM) and N-cadherin (CDH2) (Thiery et al., 2009 
Relative mRNA expression Table S1 and Figures S3 and S4. a suppressor of TGF-b signaling in a wide range of cancer types and that its loss activates TGF-b signaling.
To further study the mechanism by which MED12 suppresses TGF-b signaling, we investigated the effect of MED12
KD on key components of the TGF-b pathway. We found that MED12 KD resulted in a strong induction of TGF-bR2 protein levels ( Figures  4G and 4H) . As a result of the TGF-bR2 upregulation, SMAD2, the key mediator of TGF-b signaling, was activated as indicated by a strong increase in SMAD2 phosphorylation. Consistently, affinity-labeling assays with 125 I-TGF-b1 showed strong increase of the 125 I-labeled cell-surface TGF-bR2 upon MED12 KD in H3122 cells ( Figure S5H ). As controls, Because MED12 is part of the MEDIATOR transcriptional complex that functions in the nucleus, we assumed that MED12 would act on TGF-bR2 transcription. However, there was only a modest increase in TGF-bR2 mRNA upon MED12 KD ( Figure 4I ). Moreover, we observed a progressive increase in TGF-bR2 protein levels in time after MED12 KD . These results suggest that MED12 predominantly suppresses TGF-bR2 in a posttranscriptional manner. To investigate this, we determined the subcellular localization of MED12. We carried out nuclear and cytoplasmic fractionation of PC9 cells expressing control vector or shMED12 followed by western blotting ( Figure 4K ). Lamin A/C and SP1 were used as controls for nuclear fractions, a-TUBULIN and HSP90 for cytoplasmic fractions. Abundant nuclear MED12 was detected, consistent with its function in the MEDIATOR transcriptional complex. Unexpectedly, a significant quantity of MED12 was also present in the cytoplasmic fraction. Cytoplasmic MED12 was also seen in H3122 cells ( Figure S5K ). No cytoplasmic CDK8, another subunit of the MEDIATOR kinase module with which MED12 is known to associate closely, was detected. This suggests that cytoplasmic MED12 might have a second function distinct from its role in the MEDIATOR complex. Consistent with this, downregulation of other MEDIATOR subunits, such as CDK8 and MED13 in PC9 and H3122 cells, did not lead to upregulation of TGF-bR2 or activation of SMAD2 ( Figures 5A and 5B) and failed to confer resistance to EGFR and ALK inhibitors ( Figures 5C and 5D ). The unexpected cytoplasmic localization of MED12 prompted us to examine a potential physical interaction between MED12 and TGF-bR2. We first performed coimmunoprecipitation (coIP) experiments with Phoenix cells cotransfected with TGF-bR2 and MED12. As indicated in Figure 4L , TGF-bR2 coimmunoprecipitated with MED12, and conversely MED12 coimmunoprecipitated with TGF-bR2, indicating that MED12 interacts physically with TGF-bR2. Consistent with this, coIP experiments with the cytoplasmic fraction of untransfected PC9 cells indicate that endogenous TGF-bR2 interacts with endogenous MED12 ( Figure 4M ). As a second independent approach, we used a proximity ligation assay (PLA) to validate the TGF-bR2-MED12 interaction in situ. PLA technology allows sensitive detection of protein-protein interaction and requires two primary antibodies from different species against the proteins that are presumed to interact. Because our best antibodies against TGF-bR2 and MED12 were produced in rabbits, we generated MED12 KD PC9 cells reconstituted with Flag-Med12 to be able to use PLA technology with mouse anti-Flag to detect Med12. These reconstituted cells expressed levels of MED12 and TGF-bR2 proteins similar to those in parental cells ( Figure S6A ). The results shown in Figure S6B indicate that there is a significant in situ interaction of TGF-bR2 and MED12 in the cytoplasm of PC9 cells, which is consistent with the data from the coIP experiments above.
The observation that MED12 KD caused a strong increase of cell-surface TGF-bR2 ( Figure S5H ) suggests that MED12 could inhibit TGF-bR signaling by preventing the maturation of TGF-bR2. To test this, we performed coIP experiments with antibodies against HA tag and MED12 on Phoenix cells cotransfected with HA-TGF-bR2 and MED12 and incubated the immunoprecipitates with Endo H or PNGase F enzymes. Endo H removes oligosaccharides of glycoproteins in the endoplasmic reticulum (ER), but not the highly processed complex oligosaccharides processed in the Golgi. In contrast, PNGase F deglycosylates glycoproteins in both the ER and Golgi. As indicated in Figure S6C , in the TGF-bR2 immunoprecipitate, we observed three distinct forms of TGF-bR2: the 60 kDa form that was insensitive to both Endo H and PNGase F corresponding to unglycosylated TGF-bR2; the 70 kDa form that was sensitive to Endo H corresponding to the partially glycosylated TGF-bR2 in the ER; the smear from 80 to 100 kDa that was Endo H resistant but PNGase F sensitive corresponding to the fully glycosylated TGF-bR2. We found that only the nonprocessed and partially processed forms of TGF-bR2 coimmunoprecipitated with MED12. These data are consistent with a model in which MED12 interferes with the proper glycosylation of TGF-bR2 and hence blocks cell-surface expression of the receptor (Kim et al., 2012) .
A MED12 KD Gene Signature Has Features of EMT and Is Both Prognostic and Predictive
MED12 suppression leads to activation of TGF-b signaling and expression of mesenchymal markers, suggestive of a partial EMT-like process. Recently, EMT has been identified as a program in human CRC that correlates with poor prognosis (Loboda et al., 2011) . We therefore asked whether MED12 KD indeed induces an EMT-like process and whether the processes induced by MED12 KD are likewise associated with poor prognosis in CRC. We first compared the 237 genes that are upregulated in the MED12 KD signature (Table S2A) to the 229 genes upregulated in a more general EMT signature (see Extended Experimental Procedures; Table S2B ). We found a significant overlap of 31 genes between both signatures (p = 8.9 3 10 À23 ; Figure S7A and Table S2C ). This further supports the notion that MED12 loss initiates a partial EMT. Next we asked whether genes that are deregulated after MED12 KD predict survival in CRC. Hierarchical clustering of a set of 231 CRC tumor samples using the MED12 KD signature genes led to the identification of two groups of patients that have significantly different diseasespecific survival (DSS) ( Figure S7B ). The group with higher overall expression of signature genes that are upregulated upon MED12 KD had worse outcomes compared to the group with lower expression of the same genes. These results indicate that the processes induced by MED12 KD are associated with a poor survival in CRC patients. Next, we examined a second cohort of 270 stage III CRC patients, only some of whom were treated with 5-FU-based chemotherapy and whose responses to chemotherapy are known, to determine whether the MED12 KD signature could also predict responses to chemotherapy in patients (Salazar et al., 2011; P.R., unpublished data) . We used the MED12 KD signature genes that were also present in the microarray previously used for the expression analysis of these tumors to classify patients as MED12
KD like or MED12 wild-type (MED12WT) like (see Extended Experimental Procedures; Tables S2D and  S2M ). We found that chemotherapy did not lead to noticeable change in DSS of patients with MED12 KD -like tumors ( Figure 6A) whereas it did cause a significant increase in DSS of patients with MED12WT-like tumors ( Figure 6B ). These results indicate that the MED12 KD signature predicts response to 5-FU-based chemotherapy in CRC patients, consistent with our finding that MED12 KD confers resistance to 5-FU ( Figure S2F ). To further substantiate our finding that MED12 suppression confers resistance to cancer drugs targeting the MEK-ERK pathway, we asked whether the MED12 KD signature could predict response to MEK inhibitors in a large and heterogeneous panel of cancer cell lines of different tissue types. As MEK inhibitors are currently being evaluated to treat tumors that have activating mutations in RAS or BRAF, we focused on 152 tumor cell lines harboring either RAS or BRAF mutations for whom the IC 50 values of four different MEK inhibitors and gene-expression patterns have been determined (Garnett et al., 2012 ) (see Extended Experimental Procedures and Table S2F ). Of the 237 genes that were upregulated by MED12 KD as identified by RNA-Seq, we could read the expression levels for 170 genes in these 152 cell lines (Table S2E) . We found that high expression of these 170 genes is significantly associated with higher IC 50 s for all four MEK inhibitors in these cell lines (AZD6244, p = 0.009; CI-1040, p = 0.004; PD-0325901, p = 0.007; RDEA119, p = 0.013; Figure 6C and Table S2E ). The analysis of one of these genes, ZBED2, is shown as an example in Figure S7C . Thus the group of genes that is upregulated upon MED12 KD predicts response to MEK inhibitors in a very heterogeneous panel of cancer cell lines, consistent with our finding that MED12 acts independently of cellular context to influence cancer drug response ( Figure 6C ).
Finally, we asked whether expression of MED12
KD signature genes is associated with drug resistance to targeted agents in the clinic. We obtained pairs of tumor samples derived from three patients (cases 3, 6, and 10) that have NSCLC tumors with EGFR-activating mutations both before and after development of resistance to gefitinib (Uramoto et al., 2011) . Two of the resistant tumors did have the EGFR T790M gatekeeper mutation (cases 3 and 6). RNA was isolated from these formalin-fixed tumor slides followed by transcriptome sequencing by RNA-Seq. For each pair, we selected genes that showed a greater than 2-fold upregulation after acquisition of gefitinib resistance and then asked whether these genes overlap with the MED12 KD signature. For the tumor pair without the EGFR T790M mutation (case 10), we did observe a significant overlap of genes upregulated after acquisition of gefitinib resistance with the MED12 KD signature genes ( Figure 6D and Tables   S2G-S2L ), but not for the two tumor pairs with EGFR T790M mutation (cases 3 and 6) ( Figure S7B and Table S3 ). This result indicates that in the patient of case 10, a gene-expression program was activated upon gefitinib resistance that resembles the program induced by MED12 KD .
TGF-bR Inhibitor and TKIs Synergize to Suppress Proliferation of MED12 KD NSCLC Cells As inhibition of TGF-bR2 by RNAi resensitized MED12
KD cells to tyrosine kinase inhibitors (TKIs), we reasoned that TGF-bR inhibitors should synergize with TKIs to inhibit proliferation in MED12 KD cells. To test this, we cultured both parental and MED12 KD H3122 cells in the absence and the presence of crizotinib, the TGF-bR inhibitor LY2157299, or the combination of both drugs. Crizotinib alone potently inhibited the growth of the control, but not of the MED12 KD cells. LY2157299 alone had little effect on all cells.
However, strong synergy was seen when crizotinib was combined with LY2157299 ( Figure 7A ). The same synergistic response was also obtained when LY2157299 was combined with gefitinib in MED12 KD PC9 cells ( Figure 7B ). Moreover, the combination of LY2157299 with crizotinib or gefitinib suppressed the ERK activation driven by MED12 KD in both H3122 and PC9 cells ( Figures 7C and 7D ). These biochemical data are in line with our previous RNAi results where TGF-bR2 KD suppressed ERK activation in MED12 KD cells (Figures S4D-S4F) . Thus, the combination of TGF-bR inhibitors and TKIs might be a strategy for treating tumors with elevated TGF-b signaling.
DISCUSSION
We identify here MED12 as a candidate biomarker of response to a range of cancer drugs in a variety of cancer types through (J) There is a progressive increase in TGF-bR2 protein levels in time after MED12 KD , and the increase is associated with increased p-MEK, p-ERK, and Ncadherin. Western blotting analysis of the total lysates from the PC9 cells described in (I). All cells were treated with 25 nM gefinitib for 6 hr before lysate collection.
(K) MED12 localizes to both nucleus and cytoplasm. Western blotting analysis of the nuclear and cytoplasmic fractions prepared from PC9 cells expressing control vector or shMED12 with or without 16 hr of 25 nM gefitinib treatment. Lamin A/C and SP1 were used as marker controls for nuclear fractions, whereas a-TUBULIN and HSP90 were used as controls for cytoplasmic fractions. a previously unappreciated role of this protein in TGF-b receptor signaling. MED12 is a component of the MEDIATOR transcriptional adaptor complex that serves as a molecular bridge between the basal transcription machinery and its upstream activators (Conaway et al., 2005) . More specifically, MED12 is a subunit of the ''kinase'' module of the MEDIATOR complex, which also contains MED13, CYCLIN C, and CDK8, whose gene sequence is amplified in some 50% of colon cancers See also Figure S7 and Table S2 . (Firestein et al., 2008) . However, neither CDK8 KD nor MED13 KD caused upregulation of TGF-bR2 or conferred drug resistance, highlighting the unique role of MED12 in both TGF-bR2 activation and drug resistance. The involvement of MED12 in the response to TKIs was unexpected as most of the known genes that influence responses to TKIs involve components of signaling pathways that act downstream of or in parallel to these receptors. We reconcile this apparent discrepancy by demonstrating that part of MED12 resides in the cytosol, where it interacts with the immature forms of TGF-bR2 and inhibits its glycosylation, thereby preventing cell-surface expression (Kim et al., 2012) . Consequently, MED12 KD strongly enhances cell-surface expression of TGF-bR2 and activates TGF-b signaling. Activation of TGF-b signaling has also been linked to increased RAS-MEK-ERK signaling (reviewed by Zhang, 2009 ). Indeed we observed activation of ERK signaling by MED12 suppression, which persists in the presence of drugs like crizotinib, gefitinib, vemurafenib, seluteminib, and sorafenib (Figures 2 and S4 ), thus providing a rationale for why suppression of MED12 confers resistance to these drugs.
Our data indicate that MED12 suppression also induces an EMT-like phenotype and that this EMT-like phenotype induced by MED12 KD is associated with chemotherapy resistance in both cell lines and patients. Our data are consistent with the findings of others who also witnessed resistance to EGFR inhibitors in cell lines undergoing EMT (Fuchs et al., 2008; Yao et al., 2010) . In the clinic, EMT transdifferentiation was also seen in NSCLC patients who developed resistance to EGFR TKIs (Sequist et al., 2011; Uramoto et al., 2011) . Consistent with this, we observed in a NSCLC patient who developed resistance to gefitinib without gatekeeper T790M mutation that a program of gene expression that resembled the one induced by MED12 KD was activated ( Figure 6D ). It is at this point not clear whether patients that acquire EMT during drug resistance do so as a result of MED12 loss. This appears possible as MED12 is mutated in some 70% of uterine leiomyomas and in 5% of prostate cancers (Barbieri et al., 2012; Mä kinen et al., 2011) . We note that these mutations are highly clustered, raising the possibility that these mutations are not null alleles. (C) H3122 cells were grown in the absence or presence of 20 mM NVP-TAE684, 5 mM LY2157299, or the combination of 20 mM NVP-TAE684 and 5 mM LY2157299 for 6 hr, and the cell lysates were harvested for western blotting analysis. (D) PC9 cells were grown in the absence or presence of 25 nM gefitinib, 5 mM LY2157299, or the combination of 25 nM gefitinib and 5 mM LY2157299 for 6 hr, and the cell lysates were harvested for western blotting analysis. See also Figure S4 .
the multikinase inhibitor sorafenib. Therefore, MED12 suppression may not be a marker of intrinsic drug resistance as its constitutive suppression could well be disadvantageous to the cancer cell, but it may be acquired during drug selection to resist the therapy. That cancer cells can transiently assume a reversible drug-tolerant state was recently shown (Sharma et al., 2010) .
Finally, our data demonstrate that inhibition of TGF-b signaling in MED12
KD cells with small-molecule drugs can reverse resistance to targeted cancer drugs (Figure 7) . This raises the possibility that EMT arising during drug-resistance development as seen in NSCLC (Sequist et al., 2011; Uramoto et al., 2011) may be countered by combination with a TGF-b antagonist, a notion that can readily be tested in the clinic.
EXPERIMENTAL PROCEDURES shRNA Screens
The NKI shRNA library and the barcode screen are as described (Berns et al., 2004; Brummelkamp et al., 2006) . Additional details can be found at http:// screeninc.nki.nl/. See the Extended Experimental Procedures for details on the kinome ''dropout'' shRNA screen.
Cell Culture, Viral Transduction, and Long-Term Cell Proliferation Assays Experiments were performed as described . See the Extended Experimental Procedures for details.
Gene-Expression and Statistical Analysis
Transcriptome sequencing analysis of cell lines was performed with RNA-Seq to generate the MED12 KD gene signature, which was employed to hierarchically cluster a data set consisting of gene expression data for 231 CRC tumor samples for their outcome and to predict responses to chemotherapy in a second cohort of 270 CRC patients. Differences in DSS were determined using the Kaplan-Meier (KM) statistics. See the Extended Experimental Procedures for details.
COSMIC Cell-Line Panel Analysis
Drug-response data (IC 50 values) and gene-expression levels were obtained from Catalogue Of Somatic Mutations In Cancer (COSMIC) (Forbes et al., 2010) . See the Extended Experimental Procedures for details for the analysis.
NSCLC Patient Samples
Tumor samples derived from three patients (cases 3, 6, and 10) that have NSCLC tumors with EGFR-activating mutations both before and after acquisition of resistance to gefitinib are as described (Uramoto et al., 2011) . The institutional review board's approved informed consent for the use of the tumor tissue specimens was obtained either from all the patients or from the patient's legal guardians.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven figures, and three tables and can be found with this article online at http://dx. doi.org/10.1016/j.cell.2012.10.035.
